Glypican-3 (GPC3) is a membrane protein that is attachedby glycosylphospatidyl inositol and can also exist in asecretory form. An effective tumour marker for thediagnosis of hepatocellular carcinoma (HCC),hepatoblastoma, melanoma, testicular germ cell tumours,and Wilm’s tumour is Genebio’s antibody against Glypican-3 (GPC3). Glypican-3 (GPC3) is not detected in normal liver,benign liver, or the serum of healthy donors, but it isoverexpressed in neoplastic liver tissue and raised in serumin patients with HCC. Additionally, compared to cirrhoticliver or liver with specific lesions such dysplastic nodulesand regions of hepatic adenoma (HA) with malignanttransformation, Glypican-3 (GPC3) expression is higher inHCC liver tissue. Wilm’s tumour and hepatoblastoma aretwo examples of embryonal tumours that have high levelsof Glypican-3 (GPC3) expression, while normal surroundingtissue exhibits low or undetectable levels of GPC3expression. Glypican-3 (GPC3) expression is significantlyelevated in thyroid cancer patients in several cancer types:70% in papillary carcinoma and 100% in follicularcarcinoma. Compared to follicular adenoma, follicularcarcinoma exhibits noticeably greater levels of Glypican-3(GPC3) expression. Anaplastic carcinoma, on the otherhand, does not express Glypican-3 (GPC3).